Author: admin

“Hearing Loss Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.

The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hearing Loss Pipeline Report:

• Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years.

• Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Hearing Loss treatment

• Emerging Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.

• In July 2025, Rinri Therapeutics, a University of Sheffield spinout focused on developing regenerative cell therapies for sensorineural hearing loss (SNHL), received regulatory approval to launch its first-in-human clinical trial. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Rincell-1, a pioneering otic neural progenitor cell therapy, for a Phase I/IIa trial. Initial clinical proof-of-concept data is anticipated within 12 months of the trial’s commencement.

• In February 2025, Currently, no drug has been globally approved for the treatment of sudden hearing loss. However, the innovative drug candidate AC102 has shown encouraging results in preclinical and Phase I clinical studies. Berlin-based start-up AudioCure Pharma, backed by investors, is spearheading its research and development. InfectoPharm, a well-established mid-sized company specializing in ENT, has now joined as a key strategic partner. Based in Heppenheim, InfectoPharm is leading the latest funding round and reinforcing the existing investor group, which includes lead investor MED-EL and early-stage backer High-Tech Gründerfonds (HTGF). The collaboration aims to advance the clinical development of AC102.

• In February 2025, Sound Pharmaceuticals is excited to share that it will deliver four presentations at the upcoming Association for Research in Otolaryngology MidWinter Meeting. One of the key presentations, titled “The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus,” will be featured at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium. Organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE) committee, this symposium will offer an in-depth review of investigational treatments aimed at preventing hearing loss and promoting hearing restoration.

• In January 2025, US-based dermatology biopharma Eirion Therapeutics reported positive findings from its first-in-human, double-blind, placebo-controlled study of its topical treatment for age-related hair loss, demonstrating a six-fold increase in hair count over placebo. ET-02, the company’s most advanced therapy for androgenic alopecia, was evaluated in a trial involving 24 male patients across three US sites, successfully meeting its primary safety and tolerability endpoints. Additionally, Eirion Therapeutics is advancing a preclinical oral version of ET-02, further expanding its pipeline for hair loss treatments.

• In August 2024, Pelage Pharmaceuticals, a clinical-stage company specializing in regenerative medicine for hair loss, commenced its Phase 2a clinical trial for PP405, a novel topical small molecule aimed at treating androgenetic alopecia (pattern baldness). The first patients have been dosed, and the study will evaluate the drug’s safety and effectiveness. The trial plans to enroll 60 men and women, with PP405 designed to activate dormant hair follicle stem cells, promoting hair growth

Hearing Loss Overview

Hearing Loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight

Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:

ACOU085: Acousia Therapeutics

• Cochlear Hair Cell Regeneration: Decibel Therapeutics

• HY01: Suzhou Pharmaceutical Technology Co.,Ltd

• AC102: AudioCure Pharma GmbH

• SENS-401: Sensorion

Hearing Loss Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Hearing Loss Molecule Type

Hearing Loss Products have been categorized under various Molecule types, such as

• Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Hearing Loss Pipeline Therapeutics Assessment

• Hearing Loss Assessment by Product Type

• Hearing Loss By Stage and Product Type

• Hearing Loss Assessment by Route of Administration

• Hearing Loss By Stage and Route of Administration

• Hearing Loss Assessment by Molecule Type

• Hearing Loss by Stage and Molecule Type

DelveInsight’s Hearing Loss Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies

Some of the key companies in the Hearing Loss Therapeutics Market include:

Key companies developing therapies for Hearing Loss are – Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

Hearing Loss Pipeline Analysis:

The Hearing Loss pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.

• Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hearing Loss drugs and therapies

Hearing Loss Pipeline Market Drivers

• Rise in the Incidence of Hearing Loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Hearing Loss Market.

Hearing Loss Pipeline Market Barriers

• However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Hearing Loss Market growth.

Scope of Hearing Loss Pipeline Drug Insight

• Coverage: Global

• Key Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others

• Key Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others

• Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies

• Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers

Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials

Table of Contents

1. Hearing Loss Report Introduction

2. Hearing Loss Executive Summary

3. Hearing Loss Overview

4. Hearing Loss- Analytical Perspective In-depth Commercial Assessment

5. Hearing Loss Pipeline Therapeutics

6. Hearing Loss Late Stage Products (Phase II/III)

7. Hearing Loss Mid Stage Products (Phase II)

8. Hearing Loss Early Stage Products (Phase I)

9. Hearing Loss Preclinical Stage Products

10. Hearing Loss Therapeutics Assessment

11. Hearing Loss Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hearing Loss Key Companies

14. Hearing Loss Key Products

15. Hearing Loss Unmet Needs

16 . Hearing Loss Market Drivers and Barriers

17. Hearing Loss Future Perspectives and Conclusion

18. Hearing Loss Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hearing Loss Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details

“Ankylosing Spondylitis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market..

Some of the key takeaways from the Ankylosing Spondylitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Ankylosing Spondylitis treatment therapies with a considerable amount of success over the years.

• Ankylosing Spondylitis companies working in the treatment market are Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others, are developing therapies for the Ankylosing Spondylitis treatment

• Emerging Ankylosing Spondylitis therapies in the different phases of clinical trials are- KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others are expected to have a significant impact on the Ankylosing Spondylitis market in the coming years.

• In June 2025, UCB, a global biopharmaceutical company, has released new three-year data from its Phase 3 clinical trials and open-label extension studies evaluating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective inflammation and ankylosing spondylitis (AS). BIMZELX, a dual inhibitor targeting IL-17A and IL-17F, demonstrated long-term inflammation control and robust efficacy in managing PsA and axSpA—chronic inflammatory conditions that significantly affect patients’ physical and emotional health.

• In April 2025, A recent 3-year interim analysis from the SERENA study offers valuable insights into the safety, effectiveness, and treatment retention of secukinumab in managing psoriatic arthritis (PsA) and ankylosing spondylitis (AS). SERENA, a completed multinational, longitudinal, observational study, evaluated the long-term use, efficacy, and safety of secukinumab in patients with moderate-to-severe plaque psoriasis, active PsA, or active AS. The study included individuals diagnosed with these conditions who had been on commercially available secukinumab for at least 16 weeks prior to enrollment.

• In February 2025, UCB Canada Inc. has successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for BIMZELX® (bimekizumab), following positive reimbursement recommendations from both Canada’s Drug Agency (CDA) and Quebec’s Institut National d’Excellence en Santé et en Services Sociaux (INESSS). These endorsements pertain to the treatment of adults with active psoriatic arthritis (PsA) and ankylosing spondylitis (AS). BIMZELX® is the first and only biologic approved in Canada that inhibits both IL-17A and IL-17F. Health Canada authorized its use for active PsA on February 23, 2024, and for axial spondyloarthritis, including AS, on March 11, 2024. The recent successful negotiations with pCPA are anticipated to facilitate public reimbursement, enhancing patient access to this innovative therapy.

• In January 2025, Screening is currently underway for adults with active axial spondyloarthritis (axSpA), including ankylosing spondylitis, for a Phase 2 clinical trial in Germany testing sonelokimab. This nanobody, developed by Moonlake Immunotherapeutics, is being evaluated for its potential in treating inflammatory diseases of the skin and joints. The open-label study, named S-OLARIS (EudraCT 2024-513498-36), aims to assess the efficacy of sonelokimab in reducing inflammation in the spine and sacroiliac joints, which connect the spine to the pelvis. The trial plans to enroll approximately 25 patients, all of whom will receive a 60 mg dose of sonelokimab via subcutaneous injection.

• In December 2024, Neuron23® Inc., a clinical-stage biotechnology company dedicated to precision medicines for genetically defined neurological and immunological diseases, announced the commencement of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is a highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the JAK protein family involved in pathological immune signaling. With best-in-class potential, NEU-111 reduces signaling through multiple cytokine receptors, including those for interleukin (IL)-12, IL-23, and interferon (IFN). TYK2 is associated with various immune-mediated inflammatory diseases, including ankylosing spondylitis.

Ankylosing Spondylitis Overview

Ankylosing Spondylitis is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, causing pain, stiffness, and reduced mobility. Over time, it can lead to the fusion of spinal vertebrae, resulting in a rigid spine. AS is an autoimmune condition, often linked to the HLA-B27 gene, and typically begins in early adulthood.

Get a Free Sample PDF Report to know more about Ankylosing Spondylitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight

Emerging Ankylosing Spondylitis Drugs Under Different Phases of Clinical Development Include:

• KIN-1901: Kinevant Sciences

• Sonelokimab: MoonLake Immunotherapeutics

• QX 002N: Qyuns Therapeutics

• SHR-1314: Suzhou Zelgen Biopharmaceuticals

• SHR0302: Jiangsu HengRui MedicIne

• Jaktinib: Suzhou Zelgen Biopharmaceuticals

• Apremilast: Amgen

Ankylosing Spondylitis Route of Administration

Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Intramuscular

• Topical.

Ankylosing Spondylitis Molecule Type

Ankylosing Spondylitis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Ankylosing Spondylitis Pipeline Therapeutics Assessment

• Ankylosing Spondylitis Assessment by Product Type

• Ankylosing Spondylitis By Stage and Product Type

• Ankylosing Spondylitis Assessment by Route of Administration

• Ankylosing Spondylitis By Stage and Route of Administration

• Ankylosing Spondylitis Assessment by Molecule Type

• Ankylosing Spondylitis by Stage and Molecule Type

DelveInsight’s Ankylosing Spondylitis Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Ankylosing Spondylitis product details are provided in the report. Download the Ankylosing Spondylitis pipeline report to learn more about the emerging Ankylosing Spondylitis therapies

Some of the key companies in the Ankylosing Spondylitis Therapeutics Market include:

Key companies developing therapies for Ankylosing Spondylitis are – Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others.

Ankylosing Spondylitis Pipeline Analysis:

The Ankylosing Spondylitis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.

• Ankylosing Spondylitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ankylosing Spondylitis drugs and therapies

Ankylosing Spondylitis Pipeline Market Drivers

• Rising prevalence of ankylosing spondylitis, increase in Drug Development for Ankylosing spondylitis are some of the important factors that are fueling the Ankylosing Spondylitis Market.

Ankylosing Spondylitis Pipeline Market Barriers

• However, lack of early diagnosis of the disease, minimum participation of patients in physical activity • High treatment cost and lack of caregiver and other factors are creating obstacles in the Ankylosing Spondylitis Market growth.

Scope of Ankylosing Spondylitis Pipeline Drug Insight

• Coverage: Global

• Key Ankylosing Spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others

• Key Ankylosing Spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others

• Ankylosing Spondylitis Therapeutic Assessment: Ankylosing Spondylitis current marketed and Ankylosing Spondylitis emerging therapies

• Ankylosing Spondylitis Market Dynamics: Ankylosing Spondylitis market drivers and Ankylosing Spondylitis market barriers

Request for Sample PDF Report for Ankylosing Spondylitis Pipeline Assessment and clinical trials

Table of Contents

1. Ankylosing Spondylitis Report Introduction

2. Ankylosing Spondylitis Executive Summary

3. Ankylosing Spondylitis Overview

4. Ankylosing Spondylitis- Analytical Perspective In-depth Commercial Assessment

5. Ankylosing Spondylitis Pipeline Therapeutics

6. Ankylosing Spondylitis Late Stage Products (Phase II/III)

7. Ankylosing Spondylitis Mid Stage Products (Phase II)

8. Ankylosing Spondylitis Early Stage Products (Phase I)

9. Ankylosing Spondylitis Preclinical Stage Products

10. Ankylosing Spondylitis Therapeutics Assessment

11. Ankylosing Spondylitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ankylosing Spondylitis Key Companies

14. Ankylosing Spondylitis Key Products

15. Ankylosing Spondylitis Unmet Needs

16 . Ankylosing Spondylitis Market Drivers and Barriers

17. Ankylosing Spondylitis Future Perspectives and Conclusion

18. Ankylosing Spondylitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ankylosing Spondylitis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech

“Respiratory Syncytial Virus Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Respiratory Syncytial Virus Market.

The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Respiratory Syncytial Virus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Respiratory Syncytial Virus treatment therapies with a considerable amount of success over the years.

• Respiratory Syncytial Virus companies working in the treatment market are GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others, are developing therapies for the Respiratory Syncytial Virus treatment

• Emerging Respiratory Syncytial Virus therapies in the different phases of clinical trials are- Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others are expected to have a significant impact on the Respiratory Syncytial Virus market in the coming years.

• In June 2025, MSD’s Enflonsia (clesrovimab) has been approved by the FDA for preventing respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants entering or born during their first RSV season. Enflonsia is a long-acting monoclonal antibody that offers protection for an entire five-month RSV season with a single 105mg dose, regardless of the infant’s weight. The approval is backed by results from the Phase IIb/III CLEVER trial (NCT04767373), which showed that a single dose of Enflonsia reduced RSV-related medically attended lower respiratory infections by 60.5% and hospitalizations by 84.3% over five months, compared to placebo.

• In April 2025, GSK plc (LSE/NYSE: GSK) has announced that the Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of RSV vaccines, including GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted), for adults aged 50–59 who are at higher risk of severe RSV illness. This group includes individuals with underlying health conditions such as COPD, asthma, diabetes, heart disease, and those living in care facilities. This recommendation builds on ACIP’s earlier June 2024 vote endorsing RSV vaccination for adults aged 60–74 at increased risk, and all adults aged 75 and above. AREXVY is approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 and older, and now also in those aged 50–59 at heightened risk for RSV-related LRTD.

• In February 2025, Inhalon Biopharma, a US-based company, is preparing to initiate a clinical trial of its at-home nebulized therapy for respiratory syncytial virus (RSV) through the FluCamp program. The investigational treatment, IN-002, will be evaluated in a human challenge study in partnership with the German contract research organization (CRO) hVIVO. The CRO has confirmed plans to utilize FluCamp to recruit participants for the trial, which is scheduled to begin in 2026. FluCamp enrolls healthy volunteers to take part in clinical studies focused on developing treatments for illnesses like RSV.

• In January 2025, Shionogi’s oral antiviral candidate for respiratory syncytial virus (RSV), S-337395, has achieved its primary endpoint in a Phase II clinical trial, with some participants experiencing an 88.94% reduction in viral load. The Japanese pharmaceutical company reported positive outcomes from this Phase II human challenge study, in which volunteers were deliberately infected with RSV to assess the treatment’s effectiveness in reducing the virus’s impact.

• In December 2024, Blue Lake Biotechnology, a US-based clinical-stage company specializing in intranasal vaccines, reported that its pediatric nasal vaccine for respiratory syncytial virus (RSV), BLB201, demonstrated safety and efficacy in pediatric patients during a Phase I/IIa clinical trial.

Respiratory Syncytial Virus Overview

Respiratory syncytial virus (RSV) is a common respiratory virus that primarily affects young children and older adults. It can cause mild, cold-like symptoms in healthy individuals, but it can lead to severe respiratory infections, particularly in infants, older adults, and individuals with weakened immune systems.

Get a Free Sample PDF Report to know more about Respiratory Syncytial Virus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight

Emerging Respiratory Syncytial Virus Drugs Under Different Phases of Clinical Development Include:

• Nirsevimab (MEDI-8897): MedImmune

• Sisunatovir: ReViral

• MVA-BN-RSV Vaccine: Bavarian Nordic

• RSVpreF (PF-06928316): Pfizer

• VAC 18193 (Ad26.RSV.preF): Janssen

• mRNA-1345: ModernaTX, Inc

• GSK3844766A: GlaxoSmithKline

• RSVPreF3: GlaxoSmithKline

• STR-V003/Placebo: Starna Therapeutics

• TNM001: Zhuhai Trinomab Pharma

• Sisunatovir: Pfizer

• RSVt Vaccine: Sanofi

• Deuremidevir Hydrobromide for Suspension: Vigonvita Life Sciences

• Nirsevimab: AstraZeneca

• TNM001: Zhuhai Trinomab Pharma

• Clesrovimab: Merck Sharp & Dohme LLC

• EDP-938: Enanta Pharmaceuticals

Route of Administration

Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Respiratory Syncytial Virus Pipeline Therapeutics Assessment

• Respiratory Syncytial Virus Assessment by Product Type

• Respiratory Syncytial Virus By Stage and Product Type

• Respiratory Syncytial Virus Assessment by Route of Administration

• Respiratory Syncytial Virus By Stage and Route of Administration

• Respiratory Syncytial Virus Assessment by Molecule Type

• Respiratory Syncytial Virus by Stage and Molecule Type

DelveInsight’s Respiratory Syncytial Virus Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Respiratory Syncytial Virus product details are provided in the report. Download the Respiratory Syncytial Virus pipeline report to learn more about the emerging Respiratory Syncytial Virus therapies

Respiratory Syncytial Virus Pipeline Analysis:

The Respiratory Syncytial Virus pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.

• Respiratory Syncytial Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Respiratory Syncytial Virus drugs and therapies

Respiratory Syncytial Virus Pipeline Market Drivers

• Rising government funding for treatment and proactive government initiatives generates profitable opportunities, the growing disease rate, advent of Targeted Therapies are some of the important factors that are fueling the Respiratory Syncytial Virus Market.

Respiratory Syncytial Virus Pipeline Market Barriers

• However, lack of adequate diagnostic facilities for RSV, limited awareness among parents and other factors are creating obstacles in the Respiratory Syncytial Virus Market growth.

Scope of Respiratory Syncytial Virus Pipeline Drug Insight

• Coverage: Global

• Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others

• Key Respiratory Syncytial Virus Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others

• Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies

• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers

Request for Sample PDF Report for Respiratory Syncytial Virus Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck, IMV, Shionogi, Aridis Pharma

“Cytomegalovirus Infection Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus Infection Market.

The Cytomegalovirus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cytomegalovirus Infection Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cytomegalovirus Infection treatment therapies with a considerable amount of success over the years.

• Cytomegalovirus Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus Infection treatment

• Emerging Cytomegalovirus Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus Infection market in the coming years.

• In March 2025, ACTG, an international clinical trials network dedicated to HIV and other infectious diseases, presented encouraging results from a study examining the impact of treating asymptomatic cytomegalovirus (CMV) in individuals living with HIV. The findings suggest that CMV suppression may enhance immune function and overall physical health. Data from study A5383 were shared during an oral presentation titled, “Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV,” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.

• In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Helocyte, Inc., announced that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial. The study aims to assess the effectiveness of Triplex, a cytomegalovirus (CMV) vaccine, when given to human leukocyte antigen (HLA)-matched related stem cell donors to reduce CMV occurrences in patients undergoing hematopoietic stem cell transplantation (HSCT).

• In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrated superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.

Cytomegalovirus Infection Overview

Cytomegalovirus Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.

Get a Free Sample PDF Report to know more about Cytomegalovirus Infection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight

Emerging Cytomegalovirus Infection Drugs Under Different Phases of Clinical Development Include:

• Research programme: antiviral therapeutics TSRL

• SYN002: Synklino

• Posoleucel: AlloVir

• mRNA-1647: Moderna

• CMV TCR T cell therapy: China Immunotech

• NPC-21: Nobelpharma

• HB-101: Hookipa Biotech GmbH

• Cytomegalovirus immune globulin: Biotest

• Posoleucel: AlloVir

• VBI-1501A: VBI Vaccines

• LTV 20: Lion TCR

• Maribavir: Shire

• V160: Merck Sharp & Dohme

• Maribavir: Takeda

• Valganciclovir: CSL Behring

• Brincidofovir: Chimerix

• Everolimus: Novartis

• HB-101 vaccine: Hookipa Biotech GmbH

Cytomegalovirus Infection Route of Administration

Cytomegalovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intranasal

• Intrathecal

• Intravenous

• Oral

• Oral/Intravenous

• Parenteral

• Subcutaneous

• Subcutaneous/Intramuscular

• Transdermal

Cytomegalovirus Infection Molecule Type

Cytomegalovirus Infection Products have been categorized under various Molecule types, such as

• Antisense oligonucleotide

• Gene therapy

• Hormones

• Neuropeptides

• Oligonucleotides

• Small Molecule

• Triglyceride

Cytomegalovirus Infection Pipeline Therapeutics Assessment

• Cytomegalovirus Infection Assessment by Product Type

• Cytomegalovirus Infection By Stage and Product Type

• Cytomegalovirus Infection Assessment by Route of Administration

• Cytomegalovirus Infection By Stage and Route of Administration

• Cytomegalovirus Infection Assessment by Molecule Type

• Cytomegalovirus Infection by Stage and Molecule Type

DelveInsight’s Cytomegalovirus Infection Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cytomegalovirus Infection product details are provided in the report. Download the Cytomegalovirus Infection pipeline report to learn more about the emerging Cytomegalovirus Infection therapies

Some of the key companies in the Cytomegalovirus Infection Therapeutics Market include:

Key companies developing therapies for Cytomegalovirus Infection are – Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.

Cytomegalovirus Infection Pipeline Analysis:

The Cytomegalovirus Infection pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.

• Cytomegalovirus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cytomegalovirus Infection drugs and therapies

Cytomegalovirus Infection Pipeline Market Drivers

• Increasing Prevalence of Cytomegalovirus Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus Infection Market.

Cytomegalovirus Infection Pipeline Market Barriers

• However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus Infection Market growth.

Scope of Cytomegalovirus Infection Pipeline Drug Insight

• Coverage: Global

• Key Cytomegalovirus Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others

• Key Cytomegalovirus Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others

• Cytomegalovirus Infection Therapeutic Assessment: Cytomegalovirus Infection current marketed and Cytomegalovirus Infection emerging therapies

• Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection market drivers and Cytomegalovirus Infection market barriers

Request for Sample PDF Report for Cytomegalovirus Infection Pipeline Assessment and clinical trials

Table of Contents

1. Cytomegalovirus Infection Report Introduction

2. Cytomegalovirus Infection Executive Summary

3. Cytomegalovirus Infection Overview

4. Cytomegalovirus Infection- Analytical Perspective In-depth Commercial Assessment

5. Cytomegalovirus Infection Pipeline Therapeutics

6. Cytomegalovirus Infection Late Stage Products (Phase II/III)

7. Cytomegalovirus Infection Mid Stage Products (Phase II)

8. Cytomegalovirus Infection Early Stage Products (Phase I)

9. Cytomegalovirus Infection Preclinical Stage Products

10. Cytomegalovirus Infection Therapeutics Assessment

11. Cytomegalovirus Infection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cytomegalovirus Infection Key Companies

14. Cytomegalovirus Infection Key Products

15. Cytomegalovirus Infection Unmet Needs

16 . Cytomegalovirus Infection Market Drivers and Barriers

17. Cytomegalovirus Infection Future Perspectives and Conclusion

18. Cytomegalovirus Infection Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cytomegalovirus Infection Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics

“Acute Bacterial Skin and Skin-Structure Infection Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Bacterial Skin and Skin-Structure Infection Market.

The Acute Bacterial Skin and Skin-Structure Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Bacterial Skin and Skin-Structure Infection Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Bacterial Skin and Skin-Structure Infection treatment therapies with a considerable amount of success over the years.

• Acute Bacterial Skin and Skin-Structure Infection companies working in the treatment market are ABBVIE /Durata Therapeutics, Melinta Therapeutics, MicuRx, Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others, are developing therapies for the Acute Bacterial Skin and Skin-Structure Infection treatment

• Emerging Acute Bacterial Skin and Skin-Structure Infection therapies in the different phases of clinical trials are- DALVANCE (dalbavancin), ORBACTIV, MRX-4, Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others are expected to have a significant impact on the Acute Bacterial Skin and Skin-Structure Infection market in the coming years.

• In April 2025, Sydney-based Recce Pharmaceuticals has raised A$5.0 million through a private placement and initiated a A$10.8 million entitlement offer, totaling A$15.8 million (before costs), to fund its Phase 3 trials for synthetic anti-infective treatments targeting diabetic foot infections (DFI) and acute bacterial skin and skin structure infections (ABSSSI). Announced on April 10, the funding will primarily support a registrational Phase 3 trial for its topical DFI therapy in Indonesia, with anticipated revenue generation in 2026. The funds will also be used to begin a Phase 3 ABSSSI trial in Australia, advance other clinical programs, support an IND submission to the FDA, and provide working capital.

Acute Bacterial Skin and Skin-Structure Infection Overview

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) refers to a group of serious bacterial infections that affect the skin and underlying tissues. These infections include conditions like cellulitis, wound infections, abscesses, and major cutaneous infections that are often caused by bacteria such as Staphylococcus aureus (including MRSA) and Streptococcus pyogenes. ABSSSI typically presents with redness, swelling, pain, warmth, and sometimes fever. Due to their severity and potential for rapid progression, ABSSSIs often require prompt medical intervention, including systemic antibiotics and, in some cases, surgical drainage. Early diagnosis and appropriate treatment are crucial to prevent complications.

Get a Free Sample PDF Report to know more about Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-pipeline-insight

Emerging Acute Bacterial Skin and Skin-Structure Infection Drugs Under Different Phases of Clinical Development Include:

• DALVANCE (dalbavancin): ABBVIE /Durata Therapeutics

• ORBACTIV: Melinta Therapeutics

• MRX-4: MicuRx

• Contezolid acefosamil: MicuRx

• Zevtera: Basilea Pharmaceuticals

• Iclaprim: Motif Bio

• Levonadifloxacin: Wockhardt

• Dalbavancin: Allergan

• ceftobiprole medocaril: Basilea Pharmaceutical

• Tedizolid phosphate: Merck Sharp & Dohme LLC

• linezolid: Arrevus Inc.

• Oritavancin: The Medicines Company

• NXL103: Novexel Inc

• Daptomycin: PolyMedix, Inc.

• Xydalba: Hippocrates Research

• Kimyrsa: Melinta Therapeutics, Inc.

Acute Bacterial Skin and Skin-Structure Infection Route of Administration

Acute Bacterial Skin and Skin-Structure Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Acute Bacterial Skin and Skin-Structure Infection Molecule Type

Acute Bacterial Skin and Skin-Structure Infection Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutics Assessment

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Product Type

• Acute Bacterial Skin and Skin-Structure Infection By Stage and Product Type

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Route of Administration

• Acute Bacterial Skin and Skin-Structure Infection By Stage and Route of Administration

• Acute Bacterial Skin and Skin-Structure Infection Assessment by Molecule Type

• Acute Bacterial Skin and Skin-Structure Infection by Stage and Molecule Type

DelveInsight’s Acute Bacterial Skin and Skin-Structure Infection Report covers around 2+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Acute Bacterial Skin and Skin-Structure Infection product details are provided in the report. Download the Acute Bacterial Skin and Skin-Structure Infection pipeline report to learn more about the emerging Acute Bacterial Skin and Skin-Structure Infection therapies

Some of the key companies in the Acute Bacterial Skin and Skin-Structure Infection Therapeutics Market include:

Key companies developing therapies for Acute Bacterial Skin and Skin-Structure Infection are – Paratek Pharmaceuticals Inc., Melinta Therapeutics, Inc., Allergan PLC, Merck & Co. Inc., Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Cipher Pharmaceuticals, Menarini Group, Sandoz Inc. (Novartis), Glenmark Pharmaceuticals Ltd, Pfizer Inc, and others.

Acute Bacterial Skin and Skin-Structure Infection Pipeline Analysis:

The Acute Bacterial Skin and Skin-Structure Infection pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Bacterial Skin and Skin-Structure Infection with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Bacterial Skin and Skin-Structure Infection Treatment.

• Acute Bacterial Skin and Skin-Structure Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acute Bacterial Skin and Skin-Structure Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Bacterial Skin and Skin-Structure Infection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Bacterial Skin and Skin-Structure Infection drugs and therapies

Acute Bacterial Skin and Skin-Structure Infection Pipeline Market Drivers

• Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)(AATD) is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition

• Treatment of AATD has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of patients

Acute Bacterial Skin and Skin-Structure Infection Pipeline Market Barriers

• Need of novel and effective treatment for Acute Bacterial Skin and Skin-Structure Infection.

• Need to develop management guidelines for patients with Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)

• Need for reassessment of doses for ABSSSI

Scope of Acute Bacterial Skin and Skin-Structure Infection Pipeline Drug Insight

• Coverage: Global

• Key Acute Bacterial Skin and Skin-Structure Infection Companies: ABBVIE /Durata Therapeutics, Melinta Therapeutics, MicuRx, Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others

• Key Acute Bacterial Skin and Skin-Structure Infection Therapies: DALVANCE (dalbavancin), ORBACTIV, MRX-4, Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others

• Acute Bacterial Skin and Skin-Structure Infection Therapeutic Assessment: Acute Bacterial Skin and Skin-Structure Infection current marketed and Acute Bacterial Skin and Skin-Structure Infection emerging therapies

• Acute Bacterial Skin and Skin-Structure Infection Market Dynamics: Acute Bacterial Skin and Skin-Structure Infection market drivers and Acute Bacterial Skin and Skin-Structure Infection market barriers

Request for Sample PDF Report for Acute Bacterial Skin and Skin-Structure Infection Pipeline Assessment and clinical trials

Table of Contents

1. Acute Bacterial Skin and Skin-Structure Infection Report Introduction

2. Acute Bacterial Skin and Skin-Structure Infection Executive Summary

3. Acute Bacterial Skin and Skin-Structure Infection Overview

4. Acute Bacterial Skin and Skin-Structure Infection- Analytical Perspective In-depth Commercial Assessment

5. Acute Bacterial Skin and Skin-Structure Infection Pipeline Therapeutics

6. Acute Bacterial Skin and Skin-Structure Infection Late Stage Products (Phase II/III)

7. Acute Bacterial Skin and Skin-Structure Infection Mid Stage Products (Phase II)

8. Acute Bacterial Skin and Skin-Structure Infection Early Stage Products (Phase I)

9. Acute Bacterial Skin and Skin-Structure Infection Preclinical Stage Products

10. Acute Bacterial Skin and Skin-Structure Infection Therapeutics Assessment

11. Acute Bacterial Skin and Skin-Structure Infection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Bacterial Skin and Skin-Structure Infection Key Companies

14. Acute Bacterial Skin and Skin-Structure Infection Key Products

15. Acute Bacterial Skin and Skin-Structure Infection Unmet Needs

16 . Acute Bacterial Skin and Skin-Structure Infection Market Drivers and Barriers

17. Acute Bacterial Skin and Skin-Structure Infection Future Perspectives and Conclusion

18. Acute Bacterial Skin and Skin-Structure Infection Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ABSSSI Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review By DelveInsight | Durata Therapeutics, Melinta Therapeutics, MicuRx, Glenmark Pharma, Melinta Therapeutics, Sandoz Inc